Corpus Intelligence IC Memo — WESTCHESTER MEDICAL CENTER 2026-04-26 05:02 UTC
IC Memo — WESTCHESTER MEDICAL CENTER
Investment Committee Memorandum | NY | 696 beds | Grade C | EBITDA uplift $120.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

WESTCHESTER MEDICAL CENTER

CCN 330234 | WESTCHESTER, NY | 696 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

WESTCHESTER MEDICAL CENTER is a 696-bed large academic medical center in WESTCHESTER, NY with $1.63B in net patient revenue and a 2.6% operating margin. The hospital serves a payer mix of 23.5% Medicare, 8.4% Medicaid, and 68.1% commercial.

Thesis: Undervalued. Our ML models identify $120.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.6% to 9.9% (+736bps).

Net Revenue HCRIS$1.63B
Current EBITDA COMPUTED$41.7M
Operating Margin COMPUTED2.6%
Occupancy HCRIS80.9%
Revenue / Bed COMPUTED$2.3M
Net-to-Gross HCRIS17.7%
Distress Probability ML40.9%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
35
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of 2.6% places it above the state median. Among 35 size-comparable peers (348-1392 beds), the median margin is -19.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (348-1392), prioritizing same-state peers. 35 hospitals in the comp set.

HospitalStateBedsRevenueMargin
WESTCHESTER MEDICAL CENTER (Target)NY696$1.63B2.6%
MEMORIAL HOSPITAL FOR CANCER ANY514$4.34B-32.5%
STRONG MEMORIAL HOSPITALNY749$3.31B5.2%
MOUNT SINAI HOSPITALNY1085$3.20B-12.1%
LONG ISLAND JEWISH MEDICAL CENNY1161$2.97B-27.0%
NORTH SHORE UNIVERSITY HOSPITANY782$2.27B-50.0%
STONY BROOK UNIVERSITY HOSPITANY725$1.90B-4.9%
KALEIDA HEALTHNY954$1.38B-8.8%
UNIVERSITY HOSPITAL AT SYRACUSNY625$1.33B-17.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $120.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$34.3M+210bp18mo
Cost to Collect4.5%2.5%$32.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$32.3M+198bp12mo
A/R Days Reduction5200.0%3800.0%$19.9M+122bp9mo
Clean Claim Rate88.0%96.0%$1.0M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$34.3M
Cost to Collect
$32.7M
Denial Rate Reduction
$32.3M
A/R Days Reduction
$19.9M
Clean Claim Rate
$1.0M
Total EBITDA Uplift$120.2M
Current EBITDA$41.7M
+ RCM Uplift+$120.2M
Pro Forma EBITDA$161.9M
Current Margin2.6%
Pro Forma Margin9.9%
WC Released (1x)$62.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$64.1M$1.48B23.02x87.3%
Base (11x exit)10.0x11.0x$64.1M$1.65B25.65x91.3%
Bull Case9.0x11.0x$57.7M$2.06B35.73x104.5%
Bull (12x exit)9.0x12.0x$57.7M$2.27B39.28x108.4%
Bear Case11.0x10.0x$70.6M$855.1M12.12x64.7%
Bear (11x exit)11.0x11.0x$70.6M$963.5M13.66x68.7%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 35 hospitals with 348-1392 beds
  • Same-state prioritization (n=36)
  • Comp margins: P25=-27.9% / P50=-19.1% / P75=-9.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.